Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Hilmi Tozkir,Ufuk Usta,Necdet Sut,Ezgi Genc,Fulya Oz Puyan,Ebru Tastekin,Nuray Can,Selma Korkmaz,Busem Binboga Tutug,Mert Cezik,Osman Kostek,Tulin Deniz Yalta

doi:10.5146/tjpath.2018.01422

Abstract

Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Highlights

Melanoma has a poor prognosis [1,2]
The crucial results of the present study may be summarized as follows: i) BRAF V600 mutation was more common in older patients and tumors with BRAF V600 mutation revealed necrosis and lymphovascular invasion (LVI) more commonly than wild-type tumors, ii) BRAF V600K mutation was more common in older patients and BRAF V600K mutated tumors exhibited ulceration more commonly than tumors with BRAF V600E mutation
The BRAF V600E mutation constitutes more than 80% of BRAF mutations, and it reflects the substitution of valine to (Turk Patoloji Derg 2018, 34:134-142)

Summary

Introduction

Davies et al introduced the idea of molecular alterations as an alternative to ultraviolet (UV) signature, with BRAF (v-raf murine sarcoma viral oncogene B) V600 mutations [3], marking a milestone in the treatment of previously-incurable melanoma patients. The BRAF gene encodes a serine/threonine protein kinase, which regulates the RAF–RAS–mitogene-activated protein kinase (MAPK)–extracellular signal-regulated kinase (ERK) signaling pathway, which impacts cellular proliferation, differentiation and survival [5]. The BRAF V600E mutation causes a continuous downstream signaling of the MAPK pathway and ERK activation. Other rare mutations affecting various codons of the BRAF gene have been described [1,4,6]. The BRAF V600K mutation is said to be rare, a few recent papers have reported an occurrence rate of this mutation as high as 20% in some populations [6,7,8]

Methods

Results

Discussion

Conclusion